Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 46 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Karagiannis, Thomas [Clear All Filters]
Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis.
Diabetes, Obesity and Metabolism.
(2018). Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis..
Eur J Haematol. 98(6), 563-568.
(2017). Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.
European Journal of Haematology. 98111125151171328622526459851317339343312102118301141312212432349259292117201512520158233100(6), 563 - 568.
(2017). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy..
Core Evid. 12, 1-10.
(2017). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.
Core Evidence. Volume 12, 1 - 10.
(2017). Meta-analysis of artificial pancreas trials: methodological considerations.
The Lancet Diabetes & Endocrinology. 5(9), 685.
(2017). Meta-analysis of artificial pancreas trials: methodological considerations..
Lancet Diabetes Endocrinol. 5(9), 685.
(2017). Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis..
Expert Opin Pharmacother. 18(9), 843-851.
(2017). Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Expert Opinion on Pharmacotherapy. 18555857646565(9111111), 843 - 851.
(2017). Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications..
Ther Adv Drug Saf. 7(2), 36-8.
(2016). Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications.
Therapeutic Advances in Drug Safety. 7(2), 36 - 38.
(2016). Most add-on therapies to metformin have similar effects on HbA1c..
Evid Based Med. 21(6), 223.
(2016). Premixed insulin regimens for type 2 diabetes.
Endocrine. 5128136293852682932172681092030295868(321Suppl 2811036512641555321), 387 - 389.
(2016). Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.
Endocrine. 458 - 480.
(2016).
(2016).
(2016). Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus..
Ther Adv Endocrinol Metab. 6(2), 61-7.
(2015). Safety of dipeptidyl peptidase 4 inhibitors: a perspective review..
Ther Adv Drug Saf. 5(3), 138-46.
(2014).
(2014). Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis..
Ann Intern Med. 159(4), 262-74.
(2013).
(2012).